Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Fiche publication
Date publication
janvier 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB
Lien Pubmed
Résumé
Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM).
Mots clés
Adalimumab, administration & dosage, Adult, Anti-Inflammatory Agents, administration & dosage, Colitis, Ulcerative, blood, Crohn Disease, blood, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunologic Factors, administration & dosage, Male, Middle Aged, Remission Induction, methods, Treatment Failure, Treatment Outcome
Référence
Aliment. Pharmacol. Ther.. 2017 01;45(1):50-62